DAPAGLIFLOZIN

Brand name:

• Forxiga®

Pharmaceutical company:

ASTRAZENECA PTY LTD

Condition/indication:
(therapeutic use)

• Chronic heart failure

PBAC Submission type:

Change to existing listing (–)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – July 2023

Related medicines:

--

Submission received for:

July 2023 PBAC meeting

Opportunity for consumer comment:

Open 29/03/2023 and close 24/05/2023 (see PBS Website)

PBAC meeting:

Held on 05/07/2023

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

07/11/2023

Lodgement of required documentation:

15/11/2023

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 22/11/2023

Status:

Finalised

Government processes:

Commenced on 18/12/2023

Medicine listed on the PBS:

01/03/2024 (see PBS schedule)

---